Derma Sciences Inc. (NASDAQ:DSCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage presently has a $5.25 price target on the stock. Zacks Investment Research’s price target indicates a potential upside of 12.90% from the stock’s current price.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet raised shares of Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Derma Sciences has a consensus rating of “Buy” and an average price target of $7.25.
Derma Sciences (NASDAQ:DSCI) traded up 1.09% during trading on Tuesday, reaching $4.65. 32,599 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $4.68 and a 200-day moving average price of $4.24. The firm’s market cap is $131.62 million. Derma Sciences has a 12 month low of $2.85 and a 12 month high of $5.99.
Derma Sciences (NASDAQ:DSCI) last released its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.16. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. The firm earned $22.20 million during the quarter, compared to analyst estimates of $22.40 million. On average, analysts forecast that Derma Sciences will post ($0.04) earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the stock. Granahan Investment Management Inc. MA raised its position in shares of Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock valued at $3,188,000 after buying an additional 50,142 shares during the period. Franklin Resources Inc. boosted its stake in Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock valued at $8,322,000 after buying an additional 65,192 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares in the last quarter. Vanguard Group Inc. boosted its stake in Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock valued at $207,000 after buying an additional 7,086 shares in the last quarter. 62.44% of the stock is owned by institutional investors.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.